Kentucky Rejects Federal Peptide Compounding Policy
The Kentucky Board of Pharmacy will not extend federal enforcement discretion for six peptide bulk drug substances under state law.
Updated on Nov. 22, 2026 in Healthcare

The Kentucky Board of Pharmacy voted on November 18, 2026, to enforce state compounding rules and decline waivers for six peptides: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c. The Board confirmed the federal policy does not authorize compounding these substances in or into Kentucky, including by nonresident pharmacies.
Why it matters
The Board concluded none of the six peptides meets Kentucky compounding requirements under 201 KAR 2:076, so the federal enforcement discretion policy does not change their status in the state. Kentucky pharmacies, prescribers and patients now face a state-level bar that differs from the federal interim policy.
The Board's action covers six peptide bulk drug substances, all declined for compounding under Kentucky rules despite the federal interim policy. The Board has not set a date for reconsidering waivers and says it will continue monitoring federal developments.
The players
Kentucky Board of Pharmacy
The state regulatory body that licenses and oversees pharmacies and pharmacists in Kentucky, and that enforces the state's compounding regulation 201 KAR 2:076.
U.S. Department of Health and Human Services
The federal cabinet department whose interim enforcement discretion policy covers Section 503A compounders using the six specified peptide bulk drug substances.
The details
The Board issued a compliance alert on November 19, 2026, directing pharmacies to segregate affected inventory and notify prescribers and patients. Pharmacies may not compound prescriptions for dispensing by another pharmacy, and a central fill permit does not authorize such arrangements. Violations may constitute unprofessional conduct and result in disciplinary action.
Timeline
November 18, 2026: The Kentucky Board of Pharmacy voted to decline compounding waivers for the six peptides.
November 19, 2026: The Board issued a compliance alert confirming it will not extend federal enforcement discretion.
Market Landscape
Kentucky's decision places it apart from the federal interim policy for Section 503A compounders, which covers the same six peptides. The divergence shows how state pharmacy boards can narrow access to compounded products that federal policy has temporarily allowed.
Kentucky pharmacies cannot compound, dispense or ship preparations containing these six peptides in or into the state, even though the federal policy allows Section 503A compounders to use them. Patients whose prescriptions involve these substances may need to work with prescribers on alternatives.
The takeaway
A state rule can override a federal enforcement discretion policy for compounded drugs, so Kentucky patients and prescribers should confirm with their pharmacy whether a given peptide prescription can still be filled in the state.
What happens next
The Board will continue monitoring federal developments, including possible additions to FDA's Section 503A bulks list, which could affect future waiver considerations.
Further reading
For related coverage, see Healthcare news from across the state.
Source note: This article includes information reported by The National Law Review - A Free To Use Nationwide Database of Legal Publications.






